Longevity Biotech 2026: Senolytics, NAD+ Precursors, and Rapamycin — What the Science Says

Section 1 — The State of Longevity Science in 2026

The longevity field in 2026 sits in an awkward adolescence. The underlying biology has never been better understood — hallmarks of aging including cellular senescence, mitochondrial dysfunction, epigenetic dysregulation, and loss of proteostasis are now established science. But the translation from animal models to human interventions lags by decades, and the supplement and biotech industry has enthusiastically commercialized the excitement before the evidence is in.

This creates a genuine signal-to-noise problem for biohackers. The people most interested in longevity science are also the most likely to spend money on interventions that may be ineffective or, in some cases, harmful. A rigorous 2026 review of the major intervention categories — senolytics, NAD+ precursors, mTOR inhibitors, and the broader "longevity supplement" market — is essential.

The honest summary: the three most scientifically credible longevity interventions remain exercise, caloric restriction, and not smoking. Everything else is either early-stage, unproven in humans, or actively misleading. That does not mean emerging interventions lack promise — it means the evidence base requires honest calibration.

Section 2 — The Evidence

Senolytics target senescent cells — cells that have stopped dividing but refuse to die, accumulating with age and secreting inflammatory compounds (the SASP, senescence-associated secretory phenotype). The hypothesis is that clearing senescent cells could reduce the chronic inflammation driving age-related disease.

The Dasatinib + Quercetin combination (D+Q) is the most clinically studied senolytic. A 2024 Mayo Clinic pilot trial in 14 patients with diabetic kidney disease found approximately 40% reduction in senescent cell markers after three cycles of D+Q treatment. This is a small, open-label trial — not an RCT, not powered for clinical outcomes. A larger Phase II RCT (SENIORITY trial, ~200 participants) is ongoing with results expected in 2027. Dasatinib is an FDA-approved cancer drug with meaningful toxicity; self-administration is not advisable.

Fisetin, a plant-derived flavonoid with senolytic properties in mice, is available as a supplement. Human data is essentially nonexistent beyond a 2022 open-label feasibility study (n=40) showing measurable reduction in p21-positive cells. The supplement industry markets fisetin aggressively based almost entirely on mouse data.

NAD+ precursors — primarily NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — have become the supplement category most associated with longevity science, driven largely by David Sinclair's research and media presence. The key facts: NAD+ does decline with age; NMN and NR both raise blood NAD+ levels in humans; no RCT has demonstrated that raising NAD+ with supplementation produces longevity benefits or meaningful functional improvements in healthy adults.

The 2021 Yoshino et al. study in Science showed that 250mg/day NMN improved muscle insulin sensitivity in postmenopausal women — a specific population with specific metabolic context. The replication data in healthy middle-aged adults is considerably less impressive. Multiple 2024 studies showed negligible functional benefits from NMN in healthy adults under 50. Exercise, as multiple comparison studies have shown, produces equivalent or greater NAD+ pathway activation.

Rapamycin (sirolimus) is the most scientifically credible pharmacological longevity intervention in 2026, and simultaneously the one with the highest risk profile. An mTOR inhibitor originally developed as a transplant anti-rejection drug, rapamycin extends lifespan in every mammalian model tested, including mice where it was started in late life (equivalent to human age 60). The PEARL trial — the first prospective RCT of low-dose rapamycin in healthy aging adults — published preliminary results in 2025 showing modest improvements in immunological markers and physical function at 52 weeks with once-weekly 5mg dosing. Immunosuppressive side effects at this dosing were present but modest.

The off-label rapamycin community has grown significantly, with estimated tens of thousands of Americans using it under physician supervision. The risk calculus is not simple: periodic low-dose rapamycin is not equivalent to the continuous high-dose immunosuppression used in transplant medicine, but the long-term safety data in healthy adults does not yet exist.

Section 3 — Practical Protocol

Section 4 — What to Watch Out For

Bryan Johnson's Blueprint protocol — while generating fascinating biomarker data and media coverage — is not a guide for normal humans. His protocol involves dozens of supplements, organ-specific biomarker tracking, medically supervised interventions, and roughly $4 million per year in full implementation. His biological age rollback claims are based on epigenetic clocks that are interesting research tools but not validated clinical biomarkers. The signal in his data worth paying attention to: his structured sleep, Zone 2 cardio, and strength training protocols, which are accessible to everyone.

Verdict

Not medical advice. Consult a physician before making changes.

— iBuidl Research Team